Investor

CureDuchenne Ventures

Impact investment fund financing treatments for Duchenne muscular dystrophy, run by the CureDuchenne charity

Write a review

Biotech

Visit Website Get introducedRequest an introduction Write a Review

Own this listing? Claim it

TrustList summary

The fund serves as the investing wing of CureDuchenne, a national charity focused on curing Duchenne muscular dystrophy. It was formed in 2014 after a successful exit from an earlier equity investment.

Products and services

Impact fund: puts donor funds into companies developing Duchenne treatments.
Gene and exon-skipping therapies: investments include dystrophin-restoring approaches and other disease mechanisms.
Platform technologies: it also looks for new platforms that overcome limits in existing therapies.
Early funding: its early backing is meant to attract later investment from venture capital, biotech and pharmaceutical firms.
Reinvestment: 90% of earnings go back into Duchenne research.

Clients

Biotech companies and research projects working on Duchenne, such as Exonics Therapeutics, Capricor Therapeutics, Dyne Therapeutics and Avidity.

Key facts

Formed: 2014
Parent: CureDuchenne, a national nonprofit
Earnings reinvested: 90%

Summary written by TrustList from the business's own published information, Oct 2026.

Gallery

2 images - click to enlarge

Categories & features

Biotech

Rankings

CureDuchenne Ventures is ranked on 1 TrustList ranking at #14.

Every ranking orders its listings by their reviews, how complete the profile is and the Trust Score. CureDuchenne Ventures has no reviews yet and 3 of the 10 profile details we look for. Where no listing on a page has been reviewed, the order follows the profiles alone.

Investor · 1 ranking

#14of 52
Biotech investors
Of the 52 here, 14 also cover seed stage and 14 also cover healthtech; 15 also work in Boston and 12 also work in New York City.
Behind Lightstone Ventures, ahead of Magnetic Ventures.

As of 2026-10-31. Organic ranks only; sponsored placements are never ranks. How TrustList ranks